Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
NCT06043999 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 392
Last updated 2023-09-21
Summary
Whether to perform radical TME or salvage chemoradiotherapy after local resection of intermediate-risk T1 rectal cancer is still controversial. A study based on the National Cancer Data Center showed that, because of the need for organ preservation, rescue chemoradiotherapy after local resection of rectal cancer was used in 10% of patients with T1N0 tumors and in 40% of patients with T2N0 tumors. However, the local recurrence caused by non-TME surgery is still the focus of concern for clinicians and patients. Previous retrospective studies have shown that there is no significant difference in overall survival and disease free survival between salvage CRT group and salvage TME group for patients with early rectal cancer after local resection. Pathological pT2 after local resection is the only independent risk factor for disease-free survival. However, limited to a single center and small sample size, the recurrence caused by salvage radiotherapy and chemotherapy should still be alert. Given these concerns, there is an urgent need to identify a better treatment regimen that can ensure reliable oncologic outcomes after local resection. Therefore, with TME as the control group and salvage chemoradiotherapy as the experimental group, we conducted a prospective, randomized, multicenter, non-inferiority clinical trial of the treatment effect of patients with intermediate-risk T1 and clinical stage N0M0 rectal cancer after local resection, to provide high-level evidence-based medical evidence for the final choice of these two salvage treatment methods.
Conditions
- Chemotherapy Effect
- Rectal Cancer
Interventions
- PROCEDURE
-
Radical total mesorectal excision
Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
- OTHER
-
Salavge Adjuvant Chemoradiotherapy
Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-01
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0
NCT05164315 ·Status: TERMINATED ·Phase: NA
-
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
NCT06949098 ·Status: RECRUITING ·Phase: PHASE2
-
Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
NCT07337811 ·Status: RECRUITING ·Phase: NA
-
Transanal Versus Laparoscopic Total Mesorectal Excision: a Cohort
NCT05682794 ·Status: COMPLETED
-
Radical vs Local Excision for Rectal Cancer With Clinically Complete Remission
NCT05964530 ·Status: RECRUITING ·Phase: NA
-
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
NCT03413930 ·Status: WITHDRAWN ·Phase: NA
-
Chinese TaTME Registry Collaborative
NCT03416699 ·Status: UNKNOWN
-
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT02031939 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Multicenter, Prospective, RCT:Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
NCT03042000 ·Status: UNKNOWN ·Phase: NA
-
Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma
NCT05563922 ·Status: RECRUITING ·Phase: PHASE2
-
High Dose Radiotherapy for the Treatment of Rectal Cancer
NCT03541304 ·Status: COMPLETED
-
Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial
NCT03504449 ·Status: UNKNOWN ·Phase: NA
-
Simple Transanal Local Excision,Transanal Local Excision Following Radiotherapy Versus Total Mesorectum Excision for the Treatment of the Ultra-low T2N0M0 Rectal Cancer
NCT04098471 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
NCT04543695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers
NCT00808379 ·Status: UNKNOWN ·Phase: PHASE2
-
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
NCT03587480 ·Status: RECRUITING ·Phase: NA
-
Chemoradiotherapy After Surgery Versus Preoperative Chemoradiotherapy for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors
NCT06566222 ·Status: NOT_YET_RECRUITING
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING
-
Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer
NCT05671809 ·Status: NOT_YET_RECRUITING
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer
NCT05609149 ·Status: COMPLETED
-
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
NCT01923987 ·Status: UNKNOWN ·Phase: PHASE2
-
The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer
NCT02236884 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparing Preoperative Short-course Radiotherapy With or Without Local Boost for Rectal Cancer
NCT02498353 ·Status: UNKNOWN ·Phase: NA
-
Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy
NCT02052921 ·Status: TERMINATED ·Phase: NA